±è¼®Áø			 ¸íÀÇ

¸²ÇÁÁ¾ Ä¡·áÀÇ ´ë°¡, ±¹³» īƼ¼¼Æ÷Ä¡·á ¼±±¸ÀÚ

±è¼®Áø ¸íÀÇ

  • ¼Ò ¼Ó
    »ï¼º¼­¿ïº´¿ø
  • Áø·á°ú
    Ç÷¾×Á¾¾ç³»°ú
  • Àü¹®ºÐ¾ß
    ¸²ÇÁÁ¾, ´Ù¹ß¼º°ñ¼öÁ¾, Á¶Ç÷¸ð¼¼Æ÷À̽Ä, Ç÷±¸Å½½ÄÁõÈıº, CAR-T¼¼Æ÷Ä¡·á

±è¼®Áø ±³¼ö´Â ¸²ÇÁÁ¾ Ä¡·áÀÇ ´ë°¡ÀÌÀÚ ´ëÇÑÇ÷¾×ÇÐȸ ÀÌ»çÀåÀ» ¸Ã°í ÀÖ´Â ±¹³» Ç÷¾×ÇÐ ºÐ¾ßÀÇ ±ÇÀ§ÀÚÀÌ´Ù. ±è¼®Áø ±³¼ö´Â »ï¼º¼­¿ïº´¿øÀÌ 2021³â ±¹³» ÃÖÃʷΠīƼ(CAR T)¼¼Æ÷Ä¡·á¼¾ÅÍ °³¼Ò¸¦ ÁÖµµÇÏ´Â µî Çõ½ÅÀûÀÎ Ä¡·á µµÀÔ¿¡ ¾ÕÀå¼¹´Ù. ƯÈ÷ ¸²ÇÁÁ¾ Ä¡·á¿¡¼­ »õ ÀÌÁ¤Ç¥¸¦ Á¦½ÃÇÏ´Â ¿¬±¸ÀÚ·Î À¯¸íÇÏ´Ù. 2025³â Ç÷¾×ÇÐ ºÐ¾ß ÃÖ°í ±ÇÀ§ ÇмúÁöÀÎ 'ºí·¯µå(Blood)'¿¡ Ä¡·á°¡ ¾î·Á¿î Àç¹ß¡¤ºÒÀÀ¼º ¸²ÇÁÀý ¿Ü NK/T ¼¼Æ÷ ¸²ÇÁÁ¾(ENKTL)¿¡ ´ëÇØ ºÎÀÛ¿ëÀ» ÁÙÀ̸鼭 »ýÁ¸ ±â°£À» ´Ã¸®´Â »õ·Î¿î Ä¡·á¹ýÀ» Á¦½ÃÇÏ´Â ¿¬±¸¸¦ ¹ßÇ¥ÇÏ¿´´Ù. ³­Ä¡¼º ¸²ÇÁÁ¾ ±Øº¹À» ¼±µµÇÏ´Â Àü¹®°¡ÀÌ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °í·Á´ë ÀÇ´ë Çлç
  • °í·Á´ë ÀÇ´ë ¼®»ç
  • °í·Á´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience

ÇÐȸȰµ¿

Academic activities
  • 2024 ~ ÇöÀç´ëÇÑÇ÷¾×ÇÐȸ ÀÌ»çÀå
  • 2008 ~ ÇöÀç ¹Ì±¹ Ç÷¾×ÇÐȸ
  • 2004 ~ ÇöÀç´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
  • 2004 ~ ÇöÀç´ëÇÑÇ÷¾×ÇÐȸ
  • 2002 ~ ÇöÀç´ëÇѾÏÇÐȸ
  • 1999 ~ ÇöÀç´ëÇѳ»°úÇÐȸ
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö Blood
Á¦ ¸ñ Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö Annals of Laboratory Medicine
Á¦ ¸ñ CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Blood
Á¦ ¸ñ Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Annals of Laboratory Medicine
Á¦ ¸ñ The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Blood
Á¦ ¸ñ Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Journal of Oncology
Á¦ ¸ñ Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Bone Marrow Transplantation

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

»ï¼º¼­¿ïº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1599-3114

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

»ï¼º¼­¿ïº´¿øÀº 1994³â °³¿øÇÑ Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î º»°ü, º°°ü, ¾Ïº´µ¿À¸·Î ±¸¼ºµÅ ÀÖÀ¸¸ç ¾à 1979º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 2014³â ¾ç¼ºÀÚ Ä¡·á¼¾ÅÍ, 2015³â ¹Ì·¡ ÀÇÇаüÀÌ ¿Ï°øµÆÀ¸¸ç, ÇöÀç 2019³â ¿Ï°øÀ» ¸ñÇ¥·Î Åë¿øÄ¡·á¼¾ÅÍ °ø»ç¸¦ ÁøÇàÇϰí ÀÖ´Ù. ȯÀÚ ÇູÀ» À§ÇÑ ÀÇ·á Çõ½Å ±¸Çö, º´¿ø-¿¬±¸¼Ò-Çб³-±â¾÷ü¸¦ ¿¬°áÇÏ´Â ¹ÙÀÌ¿À ÇコÄÉ¾î ¿¬±¸ ¹× ¿¬°è »ê¾÷ÀÇ ±Û·Î¹ú Çãºê¸¦ ¸ñÇ¥·Î ÇÑ´Ù.

»ï¼º¼­¿ïº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­³²±¸ ÀÏ¿ø·Î 81

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä